Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology
Under the terms of the agreement, Merck Serono and Illlumina will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. Illumina’s successful regulatory track record was an important consideration in the collaboration, as next-generation sequencing platforms cleared by a regulatory agency could accelerate the development of an assay and facilitate the registration of a companion diagnostic.
“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”
The collaboration will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.